

L Number	Hits	Search Text	DB	Time stamp
1	32	murphy-michael.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:26
7	1495	fibroblast.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 12:54
13	542	fibroblast.clm. and (transplant or graft)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 12:55
19	378	(fibroblast.clm. and (transplant or graft)) and (collagen or decorin or glycosaminoglycan)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:01
25	48900	(424/\$3).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:01
31	132	((424/\$3).CCLS.) and ((fibroblast.clm. and (transplant or graft)) and (collagen or decorin or glycosaminoglycan))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:02
37	3232	artificial WITH skin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:18
43	1324	artificial ADJ skin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:49
49	30	(artificial ADJ skin) and ((fibroblast.clm. and (transplant or graft)) and (collagen or decorin or glycosaminoglycan))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:19
55	41	(US-4304866-\$ or US-4485096-\$ or US-4485097-\$ or US-4837024-\$ or US-4902295-\$ or US-4937323-\$ or US-4963489-\$ or US-5182111-\$ or US-5282859-\$ or US-5443950-\$ or US-5460939-\$ or US-5512475-\$ or US-5516680-\$ or US-5516681-\$ or US-5518915-\$ or US-5541107-\$ or US-5580781-\$ or US-RE35399-\$ or US-5591444-\$ or US-5613982-\$ or US-5624840-\$ or US-5639654-\$ or US-5660850-\$ or US-5665372-\$ or US-5665391-\$ or US-5800811-\$).did. or (US-5830507-\$ or US-5885829-\$ or US-5902741-\$ or US-5945101-\$ or US-5968546-\$ or US-6039760-\$ or US-6110208-\$ or US-6140039-\$ or US-6333029-\$ or US-6365149-\$ or US-4604346-\$ or US-4745098-\$ or US-5888248-\$ or US-6383220-\$).did. or (US-20010048917-\$).did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:49
58	21	murphy-michael-P\$10.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/06/12 13:26

70	1	((US-4304866-\$ or US-4485096-\$ or US-4485097-\$ or US-4837024-\$ or US-4902295-\$ or US-4937323-\$ or US-4963489-\$ or US-5182111-\$ or US-5282859-\$ or US-5443950-\$ or US-5460939-\$ or US-5512475-\$ or US-5516680-\$ or US-5516681-\$ or US-5518915-\$ or US-5541107-\$ or US-5580781-\$ or US-RE35399-\$ or US-5591444-\$ or US-5613982-\$ or US-5624840-\$ or US-5639654-\$ or US-5660850-\$ or US-5665372-\$ or US-5665391-\$ or US-5800811-\$).did. or (US-5830507-\$ or US-5885829-\$ or US-5902741-\$ or US-5945101-\$ or US-5968546-\$ or US-6039760-\$ or US-6110208-\$ or US-6140039-\$ or US-6333029-\$ or US-6365149-\$ or US-4604346-\$ or US-4745098-\$ or US-5888248-\$ or US-6383220-\$).did. or (US-20010048917-\$).did.) and decorin ((US-4304866-\$ or US-4485096-\$ or US-4485097-\$ or US-4837024-\$ or US-4902295-\$ or US-4937323-\$ or US-4963489-\$ or US-5182111-\$ or US-5282859-\$ or US-5443950-\$ or US-5460939-\$ or US-5512475-\$ or US-5516680-\$ or US-5516681-\$ or US-5518915-\$ or US-5541107-\$ or US-5580781-\$ or US-RE35399-\$ or US-5591444-\$ or US-5613982-\$ or US-5624840-\$ or US-5639654-\$ or US-5660850-\$ or US-5665372-\$ or US-5665391-\$ or US-5800811-\$).did. or (US-5830507-\$ or US-5885829-\$ or US-5902741-\$ or US-5945101-\$ or US-5968546-\$ or US-6039760-\$ or US-6110208-\$ or US-6140039-\$ or US-6333029-\$ or US-6365149-\$ or US-4604346-\$ or US-4745098-\$ or US-5888248-\$ or US-6383220-\$).did. or (US-20010048917-\$).did.) and (tissue ADJ construct)	USPAT; US-PPGPUB	2002/06/12 13:36
73	3	((US-4304866-\$ or US-4485096-\$ or US-4485097-\$ or US-4837024-\$ or US-4902295-\$ or US-4937323-\$ or US-4963489-\$ or US-5182111-\$ or US-5282859-\$ or US-5443950-\$ or US-5460939-\$ or US-5512475-\$ or US-5516680-\$ or US-5516681-\$ or US-5518915-\$ or US-5541107-\$ or US-5580781-\$ or US-RE35399-\$ or US-5591444-\$ or US-5613982-\$ or US-5624840-\$ or US-5639654-\$ or US-5660850-\$ or US-5665372-\$ or US-5665391-\$ or US-5800811-\$).did. or (US-5830507-\$ or US-5885829-\$ or US-5902741-\$ or US-5945101-\$ or US-5968546-\$ or US-6039760-\$ or US-6110208-\$ or US-6140039-\$ or US-6333029-\$ or US-6365149-\$ or US-4604346-\$ or US-4745098-\$ or US-5888248-\$ or US-6383220-\$).did. or (US-20010048917-\$).did.) and (tissue ADJ construct)	USPAT; US-PPGPUB	2002/06/12 13:36
76	1324	artificial ADJ skin	USPAT; US-PPGPUB; EPO; JPO; DERWENT	2002/06/12 13:50
130	1	bioengineered ADJ tissue ADJ construct	USPAT; US-PPGPUB; EPO; JPO; DERWENT	2002/06/12 13:56
136	6	bioengineered ADJ tissue	USPAT; US-PPGPUB; EPO; JPO; DERWENT	2002/06/12 13:57
142	1	wo adj "200029553"	USPAT; US-PPGPUB; EPO; JPO; DERWENT	2002/06/12 14:00
148	0	EP ADJ "0282746"	USPAT; US-PPGPUB; EPO; JPO; DERWENT	2002/06/12 14:01
160	7	EP ADJ "282746"	USPAT; US-PPGPUB; EPO; JPO; DERWENT	2002/06/12 14:02



US005460939A

United States Patent [19]
Hansbrough et al.

[11] **Patent Number:** **5,460,939**
[45] **Date of Patent:** **Oct. 24, 1995**

[54] **TEMPORARY LIVING SKIN REPLACEMENT**

[75] Inventors: **John F. Hansbrough**, Rancho Santa Fe; **Gail K. Naughton**, El Cajon, both of Calif.

[73] Assignee: **Advanced Tissue Sciences, Inc.**, La Jolla, Calif.

[21] Appl. No.: **200,140**

[22] Filed: **Feb. 18, 1994**

Related U.S. Application Data

[60] Continuation-in-part of Ser. No. 131,361, Oct. 4, 1993, which is a division of Ser. No. 575,518, Aug. 30, 1990, Pat. No. 5,266,480, which is a division of Ser. No. 402,104, Sep. 1, 1989, Pat. No. 5,032,508, which is a continuation-in-part of Ser. No. 242,096, Sep. 8, 1988, Pat. No. 4,963,489, which is a continuation-in-part of Ser. No. 38,110, Apr. 14, 1987, abandoned, which is a continuation-in-part of Ser. No. 36,154, Apr. 3, 1987, Pat. No. 4,721,096, which is a continuation of Ser. No. 853,569, Apr. 18, 1986, abandoned.

[51] Int. Cl. **C12N 11/00; A61F 2/10; C12M 3/00**

[52] U.S. Cl. **435/1.1; 435/240.1; 435/240.23; 424/572; 424/574; 424/93.1; 424/93.21; 424/93.7**

[58] Field of Search **435/1, 2, 240.1, 435/240.2, 240.23, 240.21; 424/93 R, 95, 529, 530, 534, 572, 574, 93 B, 93 U**

OTHER PUBLICATIONS

Hansbraugh, et al. 1993 Proc of the ABA 29th Annual Mtg. Mar. 24-27 Cincinnati, Ohio vol. 25.

Woodroof, "Biobrane A Biosynthetic Skin Prosthesis," from Burn Wound Coverings, published by CRC Press, Inc. ed. D. L. Wise Ph.D., in press, pp. 1-20 (No Pub. Date).

Hansbrough et al., 1993, "Evaluation of living biosynthetic temporary skin replacement: Human fibroblasts cultured on biobrane," Proceedings of the ABA Twenty-Fifth Annual Meeting Mar. 24-27, Cincinnati, Ohio, vol. 25.

Purdue et al., 1987, "Biosynthetic skin substitute versus frozen human cadaver allograft for temporary coverage of excised burn wounds," J. Trauma 27:155-157.

McHugh et al., 1986, "Therapeutic efficacy of biobrane in partial and full-thickness thermal injury," Surgery 100:661-664.

Frank and Bonaldi, 1985, "Inhibition of wound contraction: Comparison of full-thickness skin grafts, biobrane, and aspartate membranes," Annals of Plastic Surgery 14:103-110.

Zapata-Sirvent et al., 1985, "Comparison of biobrane and scarlet red dressings for treatment of donor site wounds," Archives of Surgery 120:743-745.

Hansbrough et al., 1984, "Clinical experience with biobrane biosynthetic dressing in the treatment of partial thickness burns," Burns 10:415-419.

Frank et al., 1983, "Comparison of biobrane, porcine, and human allograft as biologic dressings for burn wounds," J. Burn Care Rehab., 4:186-190.

Lin et al., 1982, "A comparison of IP-758 and biobrane in rats as temporary protective dressings on widely expanded meshed autografts," J. Burn Care Rehab. 3:220-222.

Zachary et al., 1982, "The use of topical antimicrobials combined with biobrane in burn wound infections," J. Trauma 22:833-836.

Bartlett, 1981, "Skin substitutes," J. Trauma 21:731-732.

Tavis et al., 1976, "Graft adherence to de-epithelialized surfaces: A comparative study," Annals of Surgery 184:594-600.

Primary Examiner—Michael G. Wityshyn

Assistant Examiner—Jane Williams

Attorney, Agent, or Firm—Pennie & Edmonds

[57] **ABSTRACT**

The present invention relates to a living skin replacement. In particular, it relates to a biosynthetic dressing material composed of a living stromal tissue prepared from stromal cells such as fibroblasts cultured upon a three-dimensional framework and a transitional covering which acts as an epidermal replacement. Such a living skin replacement provides long-term biologic coverage of full-thickness wound defects. Since human fibroblasts are known to be relatively non-antigenic when transferred to allogeneic hosts, a temporary living skin replacement made up of such cells attached to a transitional covering may replace the use of cadaveric skin allografts for achieving temporary wound closure in cases where the patients lack enough healthy skin for autografts.

12 Claims, 11 Drawing Sheets

